NasdaqGM:ALVOBiotechs
Alvotech (ALVO) Returns To Quarterly Profitability Challenging Concern Over Persistent Losses
Alvotech (NasdaqGM:ALVO) opened 2026 with Q1 revenue of US$105.9 million and basic EPS of US$0.00, alongside net income of US$1.0 million, marking a quarter where the income line moved into positive territory. The company has seen revenue range from US$153.3 million in Q4 2024 to US$168.9 million in Q4 2025, while quarterly EPS has swung between a loss of US$0.87 on a trailing twelve month basis in Q4 2024 and a gain of US$0.39 in Q1 2025 as net income shifted between profits and losses. For...